ZEEV ESTROV

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica. 2021 09 01; 106(9):2384-2396. PMID: 32732359.
      Citations:    Fields:    Translation:HumansCells
    2. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173. PMID: 34424319.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383.
      Citations:    Fields:    
    4. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130. PMID: 33853292.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    5. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924. PMID: 33901324.
      Citations: 1     Fields:    Translation:Humans
    6. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763. PMID: 32236406.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    7. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 May 18. PMID: 34007049.
      Citations:    Fields:    
    8. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021 Jul; 194(1):61-68. PMID: 33973230.
      Citations:    Fields:    
    9. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 Sep 01; 127(17):3113-3124. PMID: 33914911.
      Citations:    Fields:    
    10. Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164. PMID: 33885751.
      Citations:    Fields:    Translation:Humans
    11. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499. PMID: 33846541.
      Citations: 1     Fields:    Translation:Humans
    12. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02; 12(5):401-411. PMID: 33747356.
      Citations:    Fields:    
    13. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 Jun 01; 127(11):1894-1900. PMID: 33449377.
      Citations:    Fields:    
    14. Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6. PMID: 33551345.
      Citations: 2     Fields:    
    15. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53. PMID: 33156969.
      Citations: 2     Fields:    Translation:Humans
    16. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2021 06; 35(6):1610-1620. PMID: 33087831.
      Citations: 1     Fields:    Translation:Humans
    17. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228. PMID: 32955970.
      Citations:    Fields:    Translation:HumansCells
    18. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    19. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295. PMID: 32681739.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    20. Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331. PMID: 32697338.
      Citations: 3     Fields:    Translation:Humans
    21. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. PMID: 32546726.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    22. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677. PMID: 32324887.
      Citations: 5     Fields:    Translation:Humans
    23. Hu Z, Wang W, Thakral B, Chen Z, Estrov Z, Bueso-Ramos CE, Verstovsek S, Medeiros LJ, Wang SA. Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution. Cytometry B Clin Cytom. 2021 05; 100(3):352-360. PMID: 32157815.
      Citations:    Fields:    
    24. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492. PMID: 32099037.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    25. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513. PMID: 31895947.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    26. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511. PMID: 31999839.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    27. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459. PMID: 31999850.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    28. Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RS. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1). PMID: 31941838.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    29. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598. PMID: 31862959.
      Citations: 3     Fields:    Translation:HumansCells
    30. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959. PMID: 31537528.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    31. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150. PMID: 31682008.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    32. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085. PMID: 31645416.
      Citations: 6     Fields:    Translation:HumansCells
    33. Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One. 2019; 14(9):e0222912. PMID: 31569199.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    34. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75. PMID: 31553487.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    35. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565. PMID: 31502383.
      Citations: 5     Fields:    Translation:Humans
    36. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. PMID: 31400961.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    37. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4. PMID: 31344256.
      Citations: 1     Fields:    Translation:Humans
    38. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318. PMID: 31243771.
      Citations: 6     Fields:    Translation:Humans
    39. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      Citations: 103     Fields:    Translation:HumansCTClinical Trials
    40. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. PMID: 31076409.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    41. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864. PMID: 30924136.
      Citations: 3     Fields:    Translation:Humans
    42. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861. PMID: 30885996.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    43. Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood. 2019 05 23; 133(21):2320-2324. PMID: 30745304.
      Citations: 3     Fields:    Translation:HumansCells
    44. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7. PMID: 30651532.
      Citations: 18     Fields:    Translation:Humans
    45. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37. PMID: 30545576.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    46. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019. PMID: 30530801.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    47. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574. PMID: 30508305.
      Citations: 17     Fields:    Translation:Humans
    48. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79. PMID: 30328139.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    49. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469. PMID: 30318751.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    50. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201. PMID: 30307606.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    51. Jain P, Kanagal-Shamanna R, Konoplev S, Zuo Z, Estrov Z. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018 12; 93(12):1568-1569. PMID: 30152528.
      Citations: 7     Fields:    Translation:Humans
    52. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMID: 30319961.
      Citations: 7     
    53. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14; 9(72):33710-33718. PMID: 30263097.
      Citations: 3     Fields:    
    54. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85. PMID: 30245189.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    55. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    56. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141. PMID: 30028037.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    57. Rozovski U, Keating MJ, Estrov Z. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia? Acta Haematol. 2018; 140(1):51-54. PMID: 30114695.
      Citations: 5     Fields:    Translation:HumansCells
    58. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421. PMID: 30115541.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    59. Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol. 2019 04; 185(2):382-386. PMID: 30074241.
      Citations: 1     Fields:    Translation:Humans
    60. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39. PMID: 30071517.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    61. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984.
      Citations: 20     Fields:    Translation:Humans
    62. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747. PMID: 29723397.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    63. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20; 9(30):21268-21280. PMID: 29765537.
      Citations: 15     Fields:    
    64. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398. PMID: 29769624.
      Citations: 10     Fields:    Translation:Humans
    65. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765. PMID: 29660836.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    66. Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191. PMID: 29557496.
      Citations: 2     Fields:    Translation:HumansCells
    67. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 11; 59(11):2686-2691. PMID: 29465264.
      Citations: 7     Fields:    Translation:HumansCells
    68. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281. PMID: 29479067.
      Citations:    Fields:    Translation:Humans
    69. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234. PMID: 28859185.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    70. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832. PMID: 29358183.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    71. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2017; 8:1773. PMID: 29379494.
      Citations: 10     Fields:    
    72. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018; 7(4):e1417720. PMID: 29632735.
      Citations: 4     
    73. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727. PMID: 29515765.
      Citations: 17     Fields:    
    74. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285. PMID: 29134664.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    75. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40. PMID: 29164608.
      Citations: 10     Fields:    Translation:HumansCells
    76. Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018 Jan; 97(1):109-121. PMID: 29143068.
      Citations: 7     Fields:    Translation:HumansCells
    77. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2018 04; 32(4):960-970. PMID: 28972595.
      Citations: 47     Fields:    Translation:HumansCells
    78. Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859. PMID: 28841236.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    79. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 12; 102(12):e494-e496. PMID: 28798068.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    80. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 11 15; 141(10):2076-2081. PMID: 28722170.
      Citations: 10     Fields:    Translation:HumansCells
    81. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522. PMID: 28774880.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    82. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597. PMID: 28646517.
      Citations: 1     Fields:    Translation:Humans
    83. ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017 10; 102(10):e394-e396. PMID: 28751563.
      Citations: 4     Fields:    Translation:HumansCells
    84. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402. PMID: 28743165.
      Citations: 36     Fields:    Translation:Humans
    85. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774.
      Citations: 15     Fields:    
    86. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928. PMID: 28556489.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    87. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. PMID: 28718728.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    88. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. PMID: 28708931.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    89. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559. PMID: 28379307.
      Citations: 7     Fields:    Translation:Humans
    90. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724. PMID: 28608976.
      Citations: 6     Fields:    Translation:Humans
    91. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682. PMID: 28370157.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    92. Hidalgo-López JE, Kanagal-Shamanna R, Medeiros LJ, Estrov Z, Yin CC, Verstovsek S, Konoplev S, Jorgensen JL, Mohammad MM, Miranda RN, Zhao C, Lee J, Zuo Z, Bueso-Ramos CE. Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. J Natl Compr Canc Netw. 2017 06; 15(6):790-796. PMID: 28596259.
      Citations: 5     Fields:    Translation:Humans
    93. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606. PMID: 28370097.
      Citations: 15     Fields:    Translation:HumansCells
    94. Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866. PMID: 29296729.
      Citations: 1     Fields:    
    95. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. PMID: 28295472.
      Citations: 5     Fields:    Translation:Humans
    96. Jain P, Wang SA, Yin CC, Abaza Y, Verstovsek S, Estrov Z. A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. Blood Res. 2017 Mar; 52(1):71-73. PMID: 28401108.
      Citations:    
    97. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659. PMID: 28338082.
      Citations: 2     Fields:    
    98. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577. PMID: 28295181.
      Citations:    Fields:    Translation:HumansCells
    99. Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175. PMID: 28291640.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    100. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358. PMID: 28076892.
      Citations: 2     Fields:    Translation:HumansCells
    101. Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6. PMID: 28278723.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    102. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273. PMID: 28171709.
      Citations: 30     Fields:    Translation:Humans
    103. Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda WG. PET-positive lymphadenopathy in CLL-Not always Richter transformation. Am J Hematol. 2017 04; 92(4):405-406. PMID: 27677095.
      Citations: 3     Fields:    Translation:Humans
    104. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618. PMID: 28130399.
      Citations: 11     Fields:    Translation:HumansCells
    105. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74. PMID: 28089238.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    106. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 02 15; 198(4):1740-1747. PMID: 28077600.
      Citations: 46     Fields:    Translation:HumansCells
    107. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283. PMID: 28003274.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    108. Shah AR, Muzzafar T, Assi R, Schellingerhout D, Estrov Z, Tamamyan G, Kantarjian H, Daver N. Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. BBA Clin. 2017 Jun; 7:36-40. PMID: 28070498.
      Citations: 5     
    109. Ohanian M, Pemmaraju N, Rozovski U, Alattar ML, Estrov Z, Kundra V, Tung C, Ravandi F, Manning J, Abruzzo LV. Ocular extramedullary myeloid leukaemia. Br J Haematol. 2018 03; 180(5):738-740. PMID: 27879987.
      Citations: 3     Fields:    Translation:Humans
    110. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324. PMID: 27795561.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    111. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616. PMID: 27763690.
      Citations:    Fields:    Translation:Humans
    112. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2154-2158. PMID: 27797975.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    113. Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K, Zhang Y, Bove JE, Pierce S, Kantarjian H, Estrov Z. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 2017 01; 102(1):79-84. PMID: 27686378.
      Citations: 9     Fields:    Translation:Humans
    114. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435. PMID: 27657543.
      Citations: 21     Fields:    Translation:Humans
    115. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479. PMID: 27468087.
      Citations: 7     Fields:    Translation:Humans
    116. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol. 2016 09 15; 197(6):2522-31. PMID: 27534555.
      Citations: 11     Fields:    Translation:HumansCells
    117. Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016 08 22; 213(9):1723-40. PMID: 27481130.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    118. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491. PMID: 27463065.
      Citations: 56     Fields:    
    119. Rozovski U, Hazan-Halevy I, Calin G, Harris D, Li P, Liu Z, Keating MJ, Estrov Z. Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome. J Vis Exp. 2016 06 15; (112). PMID: 27341356.
      Citations:    Fields:    Translation:HumansCells
    120. Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol. 2016 05 15; 196(10):4400-9. PMID: 27076684.
      Citations: 13     Fields:    Translation:HumansCells
    121. Liu PP, Liu J, Jiang WQ, Carew JS, Ogasawara MA, Pelicano H, Croce CM, Estrov Z, Xu RH, Keating MJ, Huang P. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene. 2016 10 27; 35(43):5663-5673. PMID: 27065330.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    122. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 06; 101(6):e254-8. PMID: 27013651.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    123. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87. PMID: 26871476.
      Citations: 27     Fields:    Translation:HumansCells
    124. Jain P, Tang G, Huh YO, Yin CC, Zuo Z, Pemmaraju N, Estrov Z, Daver N. Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. Am J Hematol. 2016 06; 91(6):647-8. PMID: 26799924.
      Citations: 1     Fields:    Translation:HumansCells
    125. Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daver N, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J Hematol. 2016 Mar; 91(3):354-5. PMID: 26437693.
      Citations: 2     Fields:    Translation:Humans
    126. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75. PMID: 26729897.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    127. Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1969-73. PMID: 26700872.
      Citations: 2     Fields:    Translation:Humans
    128. Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov Z. Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma. 2016; 57(4):758-65. PMID: 26643954.
      Citations: 17     Fields:    Translation:HumansCells
    129. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2. PMID: 26752456.
      Citations: 8     Fields:    Translation:Humans
    130. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. ß2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73. PMID: 26588193.
      Citations: 10     Fields:    Translation:HumansCells
    131. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205.
      Citations: 32     Fields:    Translation:Humans
    132. Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma. 2016 May; 57(5):1054-9. PMID: 26402369.
      Citations: 3     Fields:    Translation:Humans
    133. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555. PMID: 26432046.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    134. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9. PMID: 25904378.
      Citations: 13     Fields:    Translation:Humans
    135. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885.
      Citations: 48     Fields:    Translation:HumansCellsCTClinical Trials
    136. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol. 2015 Aug; 90(8):752-3. PMID: 25850565.
      Citations: 2     Fields:    Translation:Humans
    137. Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015 Nov 01; 121(21):3869-76. PMID: 26218678.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    138. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. PMID: 26193999.
      Citations: 78     Fields:    Translation:HumansCells
    139. Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LV. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015 Nov; 208(11):571-4. PMID: 26382622.
      Citations: 1     Fields:    Translation:HumansCells
    140. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7. PMID: 26012362.
      Citations: 8     Fields:    Translation:HumansCells
    141. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2(6):572-82. PMID: 26288818.
      Citations: 23     Fields:    Translation:HumansCells
    142. Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2. PMID: 25808231.
      Citations: 10     Fields:    Translation:HumansCells
    143. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63. PMID: 25847930.
      Citations: 10     Fields:    Translation:Humans
    144. Kurzrock R, Estrov Z, Talpaz M, Kantarjian HM. Meir Wetzler, MD. Cancer. 2015 Jul 01; 121(13):2106-7. PMID: 25832851.
      Citations:    Fields:    Translation:Humans
    145. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. 2015 Oct; 171(2):281-284. PMID: 25824652.
      Citations:    Fields:    
    146. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7. PMID: 25683856.
      Citations: 2     Fields:    Translation:HumansCells
    147. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53. PMID: 25733697.
      Citations: 31     Fields:    Translation:Humans
    148. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81. PMID: 25530214.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    149. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7. PMID: 25573991.
      Citations: 108     Fields:    Translation:Humans
    150. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7. PMID: 25413673.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    151. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015 Jun; 56(6):1643-50. PMID: 25308294.
      Citations: 32     Fields:    Translation:Humans
    152. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4. PMID: 25368968.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    153. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Cortes J, Estrov Z. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma. 2015 May; 56(5):1392-7. PMID: 25110819.
      Citations: 14     Fields:    Translation:Humans
    154. Li J, Kurasawa Y, Wang Y, Clise-Dwyer K, Klumpp SA, Liang H, Tailor RC, Raymond AC, Estrov Z, Brandt SJ, Davis RE, Zweidler-McKay P, Amin HM, Nagarajan L. Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response. J Immunol. 2014 Nov 01; 193(9):4654-62. PMID: 25238756.
      Citations: 6     Fields:    Translation:AnimalsCells
    155. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6. PMID: 25217891.
      Citations: 1     Fields:    Translation:HumansCells
    156. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma. 2015 Apr; 56(4):1012-9. PMID: 25048874.
      Citations: 2     Fields:    Translation:Humans
    157. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501. PMID: 25043749.
      Citations: 2     Fields:    Translation:Humans
    158. Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi F. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? J Clin Oncol. 2016 Mar 01; 34(7):e57-60. PMID: 24982452.
      Citations: 5     Fields:    Translation:Humans
    159. Ohanian M, Huang RS, Yakoushina TV, Estrov Z, Juneja H, Chen L, Idowu M, Abruzzo LV. Isolated mesenteric CD20-positive myeloid sarcoma. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):e217-20. PMID: 25131853.
      Citations: 3     Fields:    Translation:Humans
    160. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-activated GM-CSFRa translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res. 2014 Sep; 12(9):1267-82. PMID: 24836891.
      Citations: 8     Fields:    Translation:HumansCells
    161. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10. PMID: 24875590.
      Citations: 19     Fields:    Translation:Humans
    162. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802. PMID: 24778152.
      Citations: 36     Fields:    Translation:HumansCells
    163. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9. PMID: 24737502.
      Citations: 50     Fields:    Translation:Humans
    164. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32. PMID: 24705492.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    165. Rozovski U, Li P, Harris D, Ohanian M, Kantarjian H, Estrov Z. Interleukin-7 receptor-a gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med. 2014 Jun; 3(3):550-4. PMID: 24678068.
      Citations: 4     Fields:    Translation:HumansCells
    166. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 01; 123(18):2783-90. PMID: 24615780.
      Citations: 31     Fields:    Translation:Humans
    167. Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, Keating MJ, Estrov Z. Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 Feb 27; 123(9):1424-6. PMID: 24578497.
      Citations: 9     Fields:    Translation:Humans
    168. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5. PMID: 24487412.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    169. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Jun; 55(6):1425-7. PMID: 23987820.
      Citations:    Fields:    Translation:HumansCells
    170. Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z. Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile. Leuk Lymphoma. 2014 Apr; 55(4):944-6. PMID: 23829280.
      Citations:    Fields:    Translation:Humans
    171. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8(12):e83830. PMID: 24376763.
      Citations: 35     Fields:    Translation:AnimalsCells
    172. Quintás-Cardama A, Grgurevic S, Rozovski U, Li P, Estrov Z, Cortes J. Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):681-5. PMID: 24060288.
      Citations:    Fields:    Translation:HumansCells
    173. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    174. Rozovski U, Keating MJ, Estrov Z. Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2013 Dec; 88(3):655-66. PMID: 23941728.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    175. Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra J. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One. 2013; 8(8):e70608. PMID: 23936456.
      Citations: 12     Fields:    Translation:HumansCells
    176. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7. PMID: 23760779.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    177. Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z. Personalized medicine in CLL: current status and future perspectives. Cancer Lett. 2014 Sep 28; 352(1):4-14. PMID: 23879961.
      Citations: 6     Fields:    Translation:Humans
    178. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561.
      Citations: 73     Fields:    Translation:HumansCells
    179. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. PMID: 23821659.
      Citations: 78     Fields:    Translation:HumansCells
    180. Benjamini O, Jain P, Konoplev SN, Yin CC, Abruzzo L, Wotherspoon AC, Dearden C, Shpall EJ, Estrov Z, Keating MJ. CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):610-3. PMID: 23800602.
      Citations: 3     Fields:    Translation:Humans
    181. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901. PMID: 23782935.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    182. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3. PMID: 23774633.
      Citations: 22     Fields:    Translation:Humans
    183. Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA, Keating MJ, Estrov Z. Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia. PLoS One. 2013; 8(6):e64678. PMID: 23750211.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    184. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53. PMID: 23733767.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    185. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013 Jun 01; 12:50. PMID: 23725032.
      Citations: 34     Fields:    Translation:HumansCells
    186. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11. PMID: 23701251.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    187. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-66. PMID: 23530930.
      Citations: 10     Fields:    Translation:HumansCells
    188. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. PMID: 23512829.
      Citations: 12     Fields:    Translation:Humans
    189. Jain P, Benjamini O, Konoplev S, Mohamed MS, Romo CG, Estrov Z. Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Nov; 54(11):2540-2. PMID: 23387894.
      Citations: 1     Fields:    Translation:Humans
    190. Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system Richter's transformation and parvovirus B19 infection. Leuk Lymphoma. 2013 Sep; 54(9):2070-2. PMID: 23320889.
      Citations: 1     Fields:    Translation:HumansCells
    191. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9. PMID: 23343175.
      Citations: 6     Fields:    Translation:Humans
    192. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor? Int J Cancer. 2013 Aug 01; 133(3):534-43. PMID: 23280377.
      Citations: 17     Fields:    Translation:Humans
    193. Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating M. Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease? Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):338-41. PMID: 23332395.
      Citations: 8     Fields:    Translation:Humans
    194. Rozovski U, Keating M, Estrov Z. The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Jul; 54(7):1364-6. PMID: 23270583.
      Citations: 7     Fields:    Translation:HumansCells
    195. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):292-5. PMID: 23265768.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    196. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):342-6. PMID: 23246163.
      Citations: 2     Fields:    Translation:HumansCells
    197. Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, Tran D, Ho M, Dawud S, Dong C, Lin HK, Hu P, Estrov Z, Bueso-Ramos CE, Darnay BG. Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS One. 2012; 7(12):e51228. PMID: 23251462.
      Citations: 19     Fields:    Translation:AnimalsCells
    198. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42. PMID: 23135353.
      Citations: 20     Fields:    Translation:HumansCells
    199. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012 Sep 27; 120(13):2768-9. PMID: 23019204.
      Citations: 12     Fields:    Translation:Humans
    200. Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):93-6. PMID: 23017332.
      Citations: 6     Fields:    Translation:Humans
    201. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 06; 489(7414):155-9. PMID: 22820254.
      Citations: 133     Fields:    Translation:HumansAnimalsCells
    202. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9. PMID: 22718840.
      Citations: 74     Fields:    Translation:Humans
    203. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31. PMID: 22665218.
      Citations: 16     Fields:    Translation:Humans
    204. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200. PMID: 22578814.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    205. Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4. PMID: 22579233.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    206. Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7. PMID: 22475363.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    207. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8. PMID: 22422826.
      Citations: 75     Fields:    Translation:HumansCellsCTClinical Trials
    208. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41. PMID: 22303899.
      Citations: 5     Fields:    Translation:Humans
    209. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20. PMID: 22360602.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    210. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9. PMID: 22072492.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    211. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3. PMID: 21868570.
      Citations: 23     Fields:    Translation:Humans
    212. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8. PMID: 21751197.
      Citations: 12     Fields:    Translation:Humans
    213. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2062-8. PMID: 21750315.
      Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
    214. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011 Dec; 42(12):1989-2000. PMID: 21733558.
      Citations: 10     Fields:    Translation:HumansCells
    215. Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z. Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One. 2011; 6(6):e21250. PMID: 21731684.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    216. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13. PMID: 21555694.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    217. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40. PMID: 21512135.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    218. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877. PMID: 21480207.
      Citations: 21     Fields:    Translation:Humans
    219. Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol Cancer Res. 2011 Apr; 9(4):507-15. PMID: 21364020.
      Citations: 30     Fields:    Translation:HumansCells
    220. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011 Sep 01; 117(17):3999-4008. PMID: 21858802.
      Citations: 35     Fields:    Translation:HumansCells
    221. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44. PMID: 20960519.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    222. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res. 2011 Apr; 35(4):526-33. PMID: 20951430.
      Citations: 5     Fields:    Translation:Humans
    223. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27. PMID: 20843246.
      Citations: 445     Fields:    Translation:HumansCTClinical Trials
    224. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010 Aug 16; 5(6):499-508. PMID: 20484983.
      Citations: 48     Fields:    Translation:HumansCells
    225. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010 Nov 18; 116(20):4251-61. PMID: 20679526.
      Citations: 55     Fields:    Translation:Humans
    226. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One. 2010 Jul 29; 5(7):e11859. PMID: 20686606.
      Citations: 32     Fields:    Translation:HumansCells
    227. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011 Dec; 29(6):1206-12. PMID: 20533075.
      Citations: 7     Fields:    Translation:HumansCells
    228. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. 2011 Oct; 29(5):1094-7. PMID: 20517635.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    229. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 01; 116(11):2673-81. PMID: 20499401.
      Citations: 21     Fields:    Translation:Humans
    230. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46. PMID: 20479284.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    231. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60. PMID: 20421540.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    232. Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26. PMID: 20372971.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    233. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res. 2010 Oct; 34(10):1320-4. PMID: 20362333.
      Citations: 6     Fields:    Translation:HumansCells
    234. Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z, Zweidler-McKay P, Brandt SJ, Agulnick A, Nagarajan L. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene. 2010 May 27; 29(21):3044-53. PMID: 20348955.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    235. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62. PMID: 20212254.
      Citations: 144     Fields:    Translation:HumansCTClinical Trials
    236. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010 Apr 08; 115(14):2852-63. PMID: 20154216.
      Citations: 103     Fields:    Translation:HumansCells
    237. Estrov Z. The leukemia stem cell. Cancer Treat Res. 2010; 145:1-17. PMID: 20306242.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    238. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6. PMID: 20008298.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    239. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24. PMID: 19826111.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    240. Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M. Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res. 2010 May; 34(5):605-9. PMID: 19800118.
      Citations: 13     Fields:    Translation:Humans
    241. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50. PMID: 19762485.
      Citations: 142     Fields:    Translation:HumansAnimalsCells
    242. Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009 Nov 12; 114(20):4361-8. PMID: 19729517.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    243. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525. PMID: 19728024.
      Citations: 2     Fields:    Translation:Humans
    244. Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S, Albitar M. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res. 2010 Feb; 34(2):173-6. PMID: 19679351.
      Citations: 2     Fields:    Translation:Humans
    245. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct; 23(10):1755-62. PMID: 19458629.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    246. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 01; 15(11):3820-6. PMID: 19458051.
      Citations: 16     Fields:    Translation:Humans
    247. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13; 2:20. PMID: 19439093.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    248. Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res. 2009 May 01; 69(9):3910-7. PMID: 19383925.
      Citations: 7     Fields:    Translation:HumansCells
    249. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi F. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009 May; 89(4):489-496. PMID: 19340529.
      Citations: 23     Fields:    Translation:Humans
    250. Estrov Z. Stem cells and somatic cells: reprogramming and plasticity. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S319-28. PMID: 19778860.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    251. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10. PMID: 19075265.
      Citations: 112     Fields:    Translation:Humans
    252. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6. PMID: 18756533.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    253. Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7. PMID: 18715642.
      Citations: 9     Fields:    Translation:Humans
    254. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer. 2008 Jul 15; 113(2):360-6. PMID: 18473351.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    255. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45. PMID: 18565853.
      Citations: 64     Fields:    Translation:Humans
    256. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73. PMID: 18482053.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    257. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9. PMID: 18495956.
      Citations: 102     Fields:    Translation:HumansCellsCTClinical Trials
    258. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 01; 68(9):3413-20. PMID: 18451169.
      Citations: 108     Fields:    Translation:HumansAnimalsCells
    259. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008 Mar 15; 112(6):1306-12. PMID: 18224667.
      Citations: 11     Fields:    Translation:HumansCells
    260. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 01; 111(11):5291-7. PMID: 18334676.
      Citations: 143     Fields:    Translation:HumansCellsCTClinical Trials
    261. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008 Mar; 7(3):464-73. PMID: 18347134.
      Citations: 143     Translation:HumansCells
    262. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96. PMID: 18245540.
      Citations: 28     Fields:    Translation:HumansCells
    263. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008 Feb 06; 100(3):184-98. PMID: 18230792.
      Citations: 154     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    264. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    265. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2009 Feb; 31(1):97-105. PMID: 18190591.
      Citations: 9     Fields:    Translation:Humans
    266. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 01; 67(23):11291-9. PMID: 18056455.
      Citations: 55     Fields:    Translation:HumansCells
    267. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6. PMID: 17593028.
      Citations: 14     Fields:    Translation:Humans
    268. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8. PMID: 17596541.
      Citations: 141     Fields:    Translation:HumansCellsCTClinical Trials
    269. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007 Apr 01; 109(7):2999-3006. PMID: 17158228.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    270. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55. PMID: 17154172.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    271. Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 2007 Apr 15; 109(8):3470-8. PMID: 17202319.
      Citations: 36     Fields:    Translation:AnimalsCells
    272. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle. 2006 Dec; 5(23):2769-77. PMID: 17172852.
      Citations: 6     Translation:HumansCells
    273. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006 Dec; 6(8):671-9. PMID: 17168672.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    274. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov; 10(5):375-88. PMID: 17097560.
      Citations: 438     Fields:    Translation:HumansAnimalsCells
    275. Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma. 2006 Oct; 47(10):2049-54. PMID: 17071475.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    276. Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion. 2006 Oct; 46(10):1795-802. PMID: 17002637.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    277. Lev EI, Estrov Z, Aboulfatova K, Harris D, Granada JF, Alviar C, Kleiman NS, Dong JF. Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thromb Haemost. 2006 Oct; 96(4):498-504. PMID: 17003929.
      Citations: 21     Fields:    Translation:HumansCells
    278. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7. PMID: 16882708.
      Citations: 232     Fields:    Translation:HumansCells
    279. Kurzrock R, Talpaz M, Li L, Estrov Z. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Leuk Lymphoma. 2006 Aug; 47(8):1651-64. PMID: 16966279.
      Citations:    Fields:    Translation:HumansCells
    280. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9. PMID: 16882711.
      Citations: 176     Fields:    Translation:HumansCellsCTClinical Trials
    281. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007 Jan; 31(1):91-5. PMID: 16828865.
      Citations: 17     Fields:    Translation:HumansCells
    282. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 01; 66(7):3737-46. PMID: 16585200.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    283. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7. PMID: 16556893.
      Citations: 53     Fields:    Translation:HumansCells
    284. Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood. 2006 Aug 01; 108(3):1001-6. PMID: 16551975.
      Citations: 4     Fields:    Translation:Humans
    285. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res. 2006 Jan 15; 12(2):340-4. PMID: 16428470.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    286. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51. PMID: 16403905.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    287. Zhou Y, Garcia-Prieto C, Carney DA, Xu RH, Pelicano H, Kang Y, Yu W, Lou C, Kondo S, Liu J, Harris DM, Estrov Z, Keating MJ, Jin Z, Huang P. OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst. 2005 Dec 07; 97(23):1781-5. PMID: 16333034.
      Citations: 22     Fields:    Translation:HumansCells
    288. Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11. PMID: 16332390.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    289. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24. PMID: 16293603.
      Citations: 48     Fields:    Translation:HumansCellsCTClinical Trials
    290. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15; 107(6):2501-6. PMID: 16291594.
      Citations: 29     Fields:    Translation:HumansCells
    291. Medeiros LJ, Estrov Z, Rassidakis GZ. Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk Res. 2006 Apr; 30(4):497-501. PMID: 16203034.
      Citations: 9     Fields:    Translation:HumansCells
    292. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005 Sep 15; 104(6):1230-6. PMID: 16078266.
      Citations: 14     Fields:    Translation:HumansCells
    293. Lev EI, Kleiman NS, Birnbaum Y, Harris D, Korbling M, Estrov Z. Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. J Vasc Res. 2005 Sep-Oct; 42(5):408-14. PMID: 16088214.
      Citations: 16     Fields:    Translation:HumansCells
    294. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005 Jul 11; 93(1):70-80. PMID: 15970928.
      Citations: 29     Fields:    Translation:HumansCells
    295. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res. 2005 May-Jun; 25(3B):1841-50. PMID: 16158916.
      Citations: 8     Fields:    Translation:HumansCells
    296. Freireich EJ, Kurzrock R, Estrov Z. Metastasis--an alternative hypothesis. Cancer. 2005 Apr 15; 103(8):1537-9. PMID: 15739196.
      Citations: 1     Fields:    Translation:HumansAnimals
    297. Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res. 2005 Apr 01; 65(7):2890-8. PMID: 15805291.
      Citations: 19     Fields:    Translation:HumansCells
    298. Guikema JE, Fenton JA, de Boer C, Kleiverda K, Brink AA, Raap AK, Estrov Z, Schuuring E, Kluin PM. Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination. Genes Chromosomes Cancer. 2005 Feb; 42(2):164-9. PMID: 15543623.
      Citations:    Fields:    Translation:HumansCells
    299. Körbling M, Robinson S, Estrov Z, Champlin R, Shpall E. Umbilical cord blood-derived cells for tissue repair. Cytotherapy. 2005; 7(3):258-61. PMID: 16081352.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    300. Zhang S, Wang D, Estrov Z, Raj S, Willerson JT, Yeh ET. Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation. 2004 Dec 21; 110(25):3803-7. PMID: 15596566.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    301. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004 Nov 01; 64(21):7927-35. PMID: 15520199.
      Citations: 55     Fields:    Translation:HumansCells
    302. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7. PMID: 15486072.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    303. Verstovsek S, Estrov Z. Arsenic derivatives as therapeutic agents for hematologic malignancies. Leuk Res. 2004 Sep; 28(9):901-3. PMID: 15234564.
      Citations: 2     Fields:    Translation:Humans
    304. Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology. 2004 Aug; 9(4):279-86. PMID: 15621735.
      Citations: 11     Fields:    Translation:HumansCells
    305. Hennessy B, Körbling M, Estrov Z. Circulating stem cells and tissue repair. Panminerva Med. 2004 Mar; 46(1):1-11. PMID: 15238877.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    306. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53. PMID: 14991544.
      Citations: 20     Fields:    Translation:Humans
    307. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004 Feb; 18(2):267-75. PMID: 14628071.
      Citations: 39     Fields:    Translation:HumansCells
    308. Faderl S, Estrov Z. Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Leuk Lymphoma. 2004 Jan; 45(1):67-71. PMID: 15061199.
      Citations: 3     Fields:    Translation:HumansCells
    309. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84. PMID: 15070700.
      Citations: 109     Fields:    Translation:HumansCells
    310. Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R. Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia. 2003 Nov; 17(11):2196-201. PMID: 14523478.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    311. Yeh ET, Zhang S, Wu HD, Körbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation. 2003 Oct 28; 108(17):2070-3. PMID: 14568894.
      Citations: 111     Fields:    Translation:HumansAnimalsCells
    312. Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M, Kurzrock R. Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3722-30. PMID: 14506164.
      Citations: 4     Fields:    Translation:HumansCells
    313. Kørbling M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med. 2003 Aug 07; 349(6):570-82. PMID: 12904523.
      Citations: 180     Fields:    Translation:HumansCells
    314. Körbling M, Estrov Z, Champlin R. Adult stem cells and tissue repair. Bone Marrow Transplant. 2003 Aug; 32 Suppl 1:S23-4. PMID: 12931235.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    315. Grunberger T, Demin P, Rounova O, Sharfe N, Cimpean L, Dadi H, Freywald A, Estrov Z, Roifman CM. Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood. 2003 Dec 01; 102(12):4153-8. PMID: 12881315.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    316. Faderl S, Estrov Z. Commentary: effect of flavonoids on normal and leukemic cells. Leuk Res. 2003 Jun; 27(6):471-3. PMID: 12648504.
      Citations: 2     Fields:    Translation:HumansCells
    317. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 01; 102(5):1866-8. PMID: 12730116.
      Citations: 8     Fields:    Translation:HumansCells
    318. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003 Aug 01; 102(3):987-95. PMID: 12689943.
      Citations: 73     Fields:    Translation:HumansCells
    319. Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003 Jul 15; 102(2):630-7. PMID: 12663443.
      Citations: 17     Fields:    Translation:HumansCells
    320. Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res. 2003 Mar; 27(3):259-66. PMID: 12537979.
      Citations: 12     Fields:    Translation:HumansCells
    321. Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res. 2003 Feb; 9(2):535-50. PMID: 12576416.
      Citations: 11     Fields:    Translation:HumansCells
    322. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):81-6. PMID: 12497210.
      Citations: 10     Fields:    Translation:Humans
    323. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002 Aug 15; 100(4):1215-9. PMID: 12149200.
      Citations: 52     Fields:    Translation:HumansCells
    324. Brouard M, Barrandon Y. Male cells in female recipients of hematopoietic-cell transplants. N Engl J Med. 2002 Jul 18; 347(3):218-20; author reply 218-20. PMID: 12124415.
      Citations:    Fields:    Translation:HumansCells
    325. Cheng K, Kurzrock R, Qiu X, Estrov Z, Ku S, Dulski KM, Wang JY, Talpaz M. Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cancer. 2002 Jul 15; 95(2):440-50. PMID: 12124845.
      Citations: 8     Fields:    Translation:AnimalsCells
    326. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9. PMID: 12008081.
      Citations: 16     Fields:    Translation:HumansCells
    327. Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol. 2002 Jun; 117(4):869-74. PMID: 12060122.
      Citations: 5     Fields:    Translation:HumansCells
    328. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun; 26(6):551-9. PMID: 12007503.
      Citations: 11     Fields:    Translation:HumansCells
    329. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4. PMID: 11964319.
      Citations: 30     Fields:    Translation:HumansCells
    330. Körbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002 Mar 07; 346(10):738-46. PMID: 11882729.
      Citations: 152     Fields:    Translation:HumansCells
    331. Ravandi F, Talpaz M, Kantarjian H, Estrov Z. Cellular signalling pathways: new targets in leukaemia therapy. Br J Haematol. 2002 Jan; 116(1):57-77. PMID: 11841398.
      Citations: 4     Fields:    Translation:HumansCells
    332. Hester J. RE: Therapeutic plasma exchange: a paired comparison of Fresenius AS104 vs. COBE Spectra. J Clin Apher. 2002; 17(1):49. PMID: 11948708.
      Citations:    Fields:    Translation:HumansCells
    333. Estrov Z, Huh YO, Ginsberg CF, Harris D, Van Q, Mirza NQ, Talpaz M, Korbling M. Ex vivo expansion of apheresis-derived peripheral blood hematopoietic progenitors. J Clin Apher. 2002; 17(1):7-16. PMID: 11948700.
      Citations:    Fields:    Translation:HumansAnimalsCells
    334. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 2002 Jan 01; 99(1):326-35. PMID: 11756188.
      Citations: 73     Fields:    Translation:HumansCells
    335. Faderl S, Estrov Z. Shift of immunoglobulin phenotypes in B-cell precursor cell lines. Leuk Res. 2002 Jan; 26(1):11-2. PMID: 11734298.
      Citations:    Fields:    Translation:HumansCells
    336. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec; 21(6A):3777-84. PMID: 11911247.
      Citations: 2     Fields:    Translation:HumansCells
    337. Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood. 2001 Sep 15; 98(6):1773-81. PMID: 11535511.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    338. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001 Sep; 108(6):851-9. PMID: 11560954.
      Citations: 95     Fields:    Translation:HumansCells
    339. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 2001 Aug; 22(8):424-7. PMID: 11473830.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    340. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001 Aug; 15(8):1165-70. PMID: 11480557.
      Citations: 11     Fields:    Translation:Humans
    341. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72. PMID: 11391574.
      Citations: 8     Fields:    Translation:Humans
    342. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9. PMID: 11309324.
      Citations: 16     Fields:    Translation:Humans
    343. Faderl S, Estrov Z. The clinical significance of caspase regulation in acute leukemia. Leuk Lymphoma. 2001 Feb; 40(5-6):471-81. PMID: 11426520.
      Citations: 2     Fields:    Translation:HumansCells
    344. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia. 2001 Jan; 15(1):57-61. PMID: 11243400.
      Citations: 6     Fields:    Translation:HumansCells
    345. Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res. 2001 Jan 01; 61(1):138-44. PMID: 11196151.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    346. Stock W, Estrov Z. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix. PMID: 11147224.
      Citations: 2     Fields:    Translation:Humans
    347. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of minimal residual disease in leukemia. Int J Oncol. 2000 Dec; 17(6):1277-87. PMID: 11078816.
      Citations: 2     Fields:    Translation:HumansCells
    348. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 01; 89(9):1976-82. PMID: 11064355.
      Citations: 30     Fields:    Translation:Humans
    349. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000 Sep 15; 96(6):2240-5. PMID: 10979972.
      Citations: 129     Fields:    Translation:Humans
    350. Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J. 2000 Aug; 14(11):1529-38. PMID: 10928987.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    351. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000 Jun 15; 95(12):3929-38. PMID: 10845930.
      Citations: 11     Fields:    Translation:HumansCells
    352. Mavligit GM, Estrov Z. CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. Am J Clin Oncol. 2000 Apr; 23(2):213-5. PMID: 10776987.
      Citations: 3     Fields:    Translation:Humans
    353. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9. PMID: 10778970.
      Citations: 13     Fields:    Translation:HumansCells
    354. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9. PMID: 10656456.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    355. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000 Jan; 36(3-4):263-73. PMID: 10674898.
      Citations: 25     Fields:    Translation:HumansCells
    356. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999 Dec 01; 94(11):3717-21. PMID: 10572084.
      Citations: 41     Fields:    Translation:Humans
    357. Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M. A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res. 1999 Dec; 5(12):3990-8. PMID: 10632330.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    358. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7. PMID: 10632337.
      Citations: 16     Fields:    Translation:HumansCells
    359. Moravcová J, Nádvorníková S, Lukásová M, Klamová H. Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood. 1999 Nov 15; 94(10):3609-11. PMID: 10610116.
      Citations: 1     Fields:    Translation:Humans
    360. Faderl S, Kurzrock R, Estrov Z. Minimal residual disease in hematologic disorders. Arch Pathol Lab Med. 1999 Nov; 123(11):1030-4. PMID: 10539902.
      Citations: 1     Fields:    Translation:Humans
    361. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999 Nov; 13(11):1881-92. PMID: 10557066.
      Citations: 32     Fields:    Translation:HumansCells
    362. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BB. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999 Oct 15; 94(8):2844-53. PMID: 10515888.
      Citations: 20     Fields:    Translation:HumansCells
    363. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar M. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999 Sep; 5(3):159-63. PMID: 10641574.
      Citations: 4     Fields:    Translation:HumansCells
    364. Lion T. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood. 1999 Aug 15; 94(4):1486-8. PMID: 10484639.
      Citations: 1     Fields:    Translation:Humans
    365. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999 Aug 03; 131(3):207-19. PMID: 10428738.
      Citations: 67     Fields:    Translation:HumansCells
    366. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15; 341(3):164-72. PMID: 10403855.
      Citations: 251     Fields:    Translation:HumansCells
    367. Faderl S, Kantarjian HM, Manshouri T, Chan CY, Pierce S, Hays KJ, Cortes J, Thomas D, Estrov Z, Albitar M. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999 Jul; 5(7):1855-61. PMID: 10430092.
      Citations: 5     Fields:    Translation:HumansCells
    368. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66. PMID: 10430080.
      Citations: 17     Fields:    Translation:Humans
    369. Beaupre DM, Talpaz M, Marini FC, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R. Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res. 1999 Jun 15; 59(12):2971-80. PMID: 10383163.
      Citations: 14     Fields:    Translation:HumansCells
    370. Mavligit GM, Estrov Z, Ayala A. Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining. Am J Clin Oncol. 1999 Jun; 22(3):320-2. PMID: 10362346.
      Citations:    Fields:    Translation:Humans
    371. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999 May 01; 93(9):2755-9. PMID: 10216068.
      Citations: 9     Fields:    Translation:Humans
    372. Estrov Z, Freedman MH. Detection of residual disease in acute lymphoblastic leukemia of childhood. Leuk Lymphoma. 1999 Mar; 33(1-2):47-52. PMID: 10194120.
      Citations:    Fields:    Translation:HumansAnimals
    373. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999 Mar 01; 93(5):1668-76. PMID: 10029596.
      Citations: 32     Fields:    Translation:HumansCells
    374. Faderl S, Estrov Z. Detection of residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1999 Jan 14; 340(2):152-3; author reply 153-4. PMID: 9917220.
      Citations: 1     Fields:    Translation:Humans
    375. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol. 1999; 457:217-36. PMID: 10500797.
      Citations: 32     Fields:    Translation:HumansAnimals
    376. Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich EJ, Pierce S, Estey E. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999 Jan; 23(1):63-9. PMID: 9933137.
      Citations: 2     Fields:    Translation:Humans
    377. Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol. 1999 Jan; 6(1):79-84. PMID: 9874668.
      Citations: 17     Fields:    Translation:HumansCells
    378. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7. PMID: 9787143.
      Citations: 39     Fields:    Translation:HumansCells
    379. Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta K. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol. 1998 Nov 01; 161(9):4702-8. PMID: 9794400.
      Citations: 6     Fields:    Translation:HumansCells
    380. Wright-Browne V, Schnee AM, Jenkins MA, Thall PF, Aggarwal BB, Talpaz M, Estrov Z. Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. Leuk Lymphoma. 1998 Aug; 30(5-6):583-9. PMID: 9711920.
      Citations: 4     Fields:    Translation:HumansCells
    381. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998 Jul; 4(7):1661-72. PMID: 9676840.
      Citations: 20     Fields:    Translation:HumansCells
    382. Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, Estrov Z. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk Lymphoma. 1998 Jul; 30(3-4):279-92. PMID: 9713960.
      Citations: 1     Fields:    Translation:HumansCells
    383. Faderl S, Estrov Z. The clinical significance of detection of residual disease in childhood ALL. Crit Rev Oncol Hematol. 1998 Jun; 28(1):31-55. PMID: 9715769.
      Citations:    Fields:    Translation:Humans
    384. Faderl S, Estrov Z. Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance. Cytokines Cell Mol Ther. 1998 Jun; 4(2):73-85. PMID: 9681246.
      Citations:    Fields:    Translation:Humans
    385. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998 Jun 01; 91(11):3995-4019. PMID: 9596644.
      Citations: 42     Fields:    Translation:Humans
    386. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998 Apr; 16(4):1526-31. PMID: 9552062.
      Citations: 7     Fields:    Translation:Humans
    387. Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res. 1998 Apr; 22(4):341-53. PMID: 9669839.
      Citations: 6     Fields:    Translation:HumansCells
    388. Liu J, Hadjokas N, Mosley B, Estrov Z, Spence MJ, Vestal RE. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine. 1998 Apr; 10(4):295-302. PMID: 9617575.
      Citations: 19     Fields:    Translation:HumansCells
    389. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat. 1998 Mar; 48(2):165-74. PMID: 9596488.
      Citations: 11     Fields:    Translation:Humans
    390. Kurzrock R, Estrov Z, Ku S, Leonard M, Talpaz M. Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. J Lab Clin Med. 1998 Mar; 131(3):261-8. PMID: 9523851.
      Citations:    Fields:    Translation:HumansCells
    391. Kurzrock R, Talpaz M, Beran M, Harris D, Estrov Z. DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. Leukemia. 1998 Feb; 12(2):242-6. PMID: 9519789.
      Citations:    Fields:    Translation:HumansCells
    392. Peleg S, Qiu H, Reddy S, Harris D, Van Q, Estey EH, Talpaz M, Estrov Z. 1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production. J Clin Invest. 1997 Oct 01; 100(7):1716-24. PMID: 9312169.
      Citations: 3     Fields:    Translation:HumansCells
    393. Wetzler M, Kurzrock R, Estrov Z, Barone S, Estey E, Talpaz M. Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. Leuk Res. 1997 Jun; 21(6):519-27. PMID: 9279363.
      Citations:    Fields:    Translation:HumansCells
    394. Wright-Browne V, McClain KL, Talpaz M, Ordonez N, Estrov Z. Physiology and pathophysiology of dendritic cells. Hum Pathol. 1997 May; 28(5):563-79. PMID: 9158705.
      Citations: 12     Fields:    Translation:HumansCells
    395. Estrov Z, Talpaz M. Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Leuk Lymphoma. 1997 Feb; 24(5-6):379-91. PMID: 9086432.
      Citations:    Fields:    Translation:HumansAnimals
    396. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997 Jan 30; 336(5):317-23. PMID: 9011783.
      Citations: 14     Fields:    Translation:HumansCells
    397. McClain K, Estrov Z, Raju U, Kelley PK, Aggarwal BB. Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes. Methods. 1997 Jan; 11(1):83-7. PMID: 8990093.
      Citations:    Fields:    Translation:HumansCells
    398. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996 Nov 15; 88(10):3987-97. PMID: 8916965.
      Citations: 11     Fields:    Translation:HumansCells
    399. Lapidot T, Grunberger T, Vormoor J, Estrov Z, Kollet O, Bunin N, Zaizov R, Williams DE, Freedman MH. Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice. Blood. 1996 Oct 01; 88(7):2655-64. PMID: 8839860.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    400. Estrov Z, Talpaz M, Ku S, Harris D, LaPushin R, Koller CA, Hirsh-Ginsberg C, Huh Y, Yee G, Kurzrock R. Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia. 1996 Sep; 10(9):1534-43. PMID: 8751477.
      Citations: 4     Fields:    Translation:HumansCells
    401. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer. 1996 May 16; 66(4):515-9. PMID: 8635867.
      Citations: 30     Fields:    Translation:HumansCells
    402. Sarris AH, Talpaz M, Deisseroth AB, Estrov Z. Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors. Leukemia. 1996 May; 10(5):757-65. PMID: 8656668.
      Citations: 2     Fields:    Translation:HumansCells
    403. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol. 1996 Mar; 166(3):618-30. PMID: 8600166.
      Citations: 8     Fields:    Translation:HumansCells
    404. Estrov Z, Talpaz M. Role of interleukin-1 beta converting enzyme (ICE) in leukemia. Cytokines Mol Ther. 1996 Mar; 2(1):1-11. PMID: 9384684.
      Citations:    Fields:    Translation:HumansAnimalsCells
    405. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. Detection of minimal residual disease in all: biology, methods, and applications. Cancer Treat Res. 1996; 84:149-66. PMID: 8724630.
      Citations:    Fields:    Translation:Humans
    406. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Leuk Lymphoma. 1996 Jan; 20(3-4):181-97. PMID: 8624456.
      Citations: 1     Fields:    Translation:Humans
    407. Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey EH, Talpaz M. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood. 1995 Dec 15; 86(12):4594-602. PMID: 8541550.
      Citations: 8     Fields:    Translation:HumansCells
    408. Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res. 1995 Oct; 15(10):905-13. PMID: 8564713.
      Citations: 15     Fields:    Translation:HumansCells
    409. Kurzrock R, Wetzler M, Estrov Z, Talpaz M. Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias. Cytokines Mol Ther. 1995 Sep; 1(3):177-84. PMID: 9384674.
      Citations: 2     Fields:    Translation:HumansAnimals
    410. Estrov Z, Talpaz M, Estey EH, Strassmann G. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation. Exp Hematol. 1995 Sep; 23(10):1080-7. PMID: 7544738.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    411. Roberts WM, Estrov Z, Zipf TF. Detection of minimal residual disease in acute lymphoblastic leukemia. Blood. 1995 Aug 01; 86(3):1237-9. PMID: 7620179.
      Citations:    Fields:    Translation:Humans
    412. Estrov Z, Kurzrock R, Talpaz M. Cytokines and their antagonists in myeloid disorders. Semin Hematol. 1995 Jul; 32(3):220-31. PMID: 7570065.
      Citations:    Fields:    Translation:HumansAnimals
    413. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995 Jun; 98(6):551-8. PMID: 7539977.
      Citations: 10     Fields:    Translation:HumansCells
    414. Attias D, Grunberger T, Vanek W, Estrov Z, Cohen A, Lau R, Freedman MH. B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts. Leukemia. 1995 May; 9(5):884-8. PMID: 7769852.
      Citations: 2     Fields:    Translation:HumansCells
    415. Roberts WM, Zipf TF, Kitchingman GR, Tubergen DG, Estrov Z. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications. Cytokines Mol Ther. 1995 Mar; 1(1):65-9. PMID: 9384665.
      Citations:    Fields:    Translation:Humans
    416. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia. 1995 Feb; 9(2):321-8. PMID: 7869771.
      Citations: 4     Fields:    Translation:Humans
    417. Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz M. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res. 1995 Jan; 19(1):23-34. PMID: 7837815.
      Citations: 8     Fields:    Translation:HumansCells
    418. Estrov Z, Kurzrock R, Talpaz M. Interleukin-1 and its inhibitors: implications for disease biology and therapy. Cancer Treat Res. 1995; 80:51-82. PMID: 8821574.
      Citations:    Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    419. Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M. Dosing of thioTEPA for myeloablative therapy. Cancer Chemother Pharmacol. 1995; 37(1-2):155-60. PMID: 7497586.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    420. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma. 1994 Dec; 16(1-2):79-88. PMID: 7535143.
      Citations: 2     Fields:    Translation:HumansCells
    421. Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994 Nov 01; 84(9):3142-7. PMID: 7949186.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    422. Ferrajoli A, Talpaz M, Ordonez NG, Stanley ER, Hirsch-Ginsberg C, Zipf TF, Wetzler M, Kurzrock R, Estrov Z. Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. Stem Cells. 1994 Nov; 12(6):638-49. PMID: 7533582.
      Citations:    Fields:    Translation:HumansCells
    423. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994 Oct; 94(4):1383-9. PMID: 7929813.
      Citations: 15     Fields:    Translation:HumansCells
    424. Ferrajoli A, Talpaz M, Zipf TF, Hirsch-Ginsberg C, Estey E, Wolpe SD, Estrov Z. Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia. 1994 May; 8(5):798-805. PMID: 8182937.
      Citations: 3     Fields:    Translation:HumansCells
    425. Estrov Z, Ouspenskaia MV, Zipf TF, Tubergen DG, Roberts WM. Minimal residual leukaemia. Lancet. 1994 Apr 02; 343(8901):858-9. PMID: 7908106.
      Citations:    Fields:    Translation:Humans
    426. Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. Cancer Res. 1994 Apr 01; 54(7):1837-42. PMID: 8137298.
      Citations: 3     Fields:    Translation:HumansCells
    427. Estrov Z, Ouspenskaia MV, Felix EA, McClain KL, Lee MS, Harris D, Pinkel DP, Zipf TF. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia. 1994 Jan; 8(1):46-52. PMID: 8289497.
      Citations: 3     Fields:    Translation:HumansCells
    428. Ferrajoli A, Zipf TF, Talpaz M, Felix EA, Estrov Z. Growth factors controlling interleukin-4 action on hematopoietic progenitors. Ann Hematol. 1993 Dec; 67(6):277-84. PMID: 7506581.
      Citations: 1     Fields:    Translation:HumansCells
    429. Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med. 1993 Oct; 234(4):417-20. PMID: 7691980.
      Citations: 8     Fields:    Translation:Humans
    430. McClain K, Estrov Z, Chen H, Mahoney DH. Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol. 1993 Sep; 85(1):57-62. PMID: 8251410.
      Citations: 6     Fields:    Translation:HumansCells
    431. Estrov Z, Re GG, Zipf TF. Immature and differentiated neoplastic populations in acute lymphoid leukemia of childhood: biological and clinical implications. Leuk Lymphoma. 1993 Sep; 11(1-2):1-7. PMID: 8220141.
      Citations: 1     Fields:    Translation:Humans
    432. Estrov Z, Kurzrock R, Talpaz M. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Leuk Lymphoma. 1993 Aug; 10(6):407-18. PMID: 8401177.
      Citations: 1     Fields:    Translation:HumansAnimals
    433. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 01; 82(3):691-703. PMID: 8338938.
      Citations: 42     Fields:    Translation:Humans
    434. Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 1993 Jul 15; 53(14):3289-93. PMID: 8324740.
      Citations:    Fields:    Translation:HumansCells
    435. Estrov Z. Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia. Semin Hematol. 1993 Jul; 30(3 Suppl 3):35-6. PMID: 7694373.
      Citations:    Fields:    Translation:HumansCells
    436. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med. 1993 Mar 01; 177(3):763-74. PMID: 8382256.
      Citations: 17     Fields:    Translation:HumansCells
    437. Ferrajoli A, Talpaz M, Kurzrock R, Estrov Z. Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells. 1993 Mar; 11(2):112-9. PMID: 8384506.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    438. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. 1993 Feb; 7(2):214-20. PMID: 8426475.
      Citations: 4     Fields:    Translation:HumansCells
    439. Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol. 1993 Jan; 21(1):80-5. PMID: 8417962.
      Citations: 6     Fields:    Translation:Humans
    440. Zadik Z, Estrov Z, Karov Y, Hahn T, Barak Y. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report. J Pediatr Endocrinol. 1993 Jan-Mar; 6(1):79-83. PMID: 8374694.
      Citations: 5     Fields:    Translation:HumansCells
    441. Wetzler M, Talpaz M, Estrov Z, Kurzrock R. CML: mechanisms of disease initiation and progression. Leuk Lymphoma. 1993; 11 Suppl 1:47-50. PMID: 8251916.
      Citations: 2     Fields:    Translation:Humans
    442. Estrov Z, Talpaz M, Wetzler M, Kurzrock R. The modulatory hematopoietic activities of leukemia inhibitory factor. Leuk Lymphoma. 1992 Sep; 8(1-2):1-7. PMID: 1493463.
      Citations:    Fields:    Translation:HumansAnimals
    443. Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, Gutterman JU. The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. Exp Hematol. 1992 Aug; 20(7):886-90. PMID: 1628706.
      Citations:    Fields:    Translation:HumansCells
    444. Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol. 1992 Jun; 20(5):558-64. PMID: 1587302.
      Citations:    Fields:    Translation:HumansCells
    445. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 1992 Apr 15; 79(8):1938-45. PMID: 1373331.
      Citations: 15     Fields:    Translation:HumansCells
    446. Freedman MH, Cohen A, Grunberger T, Bunin N, Luddy RE, Saunders EF, Shahidi N, Lau A, Estrov Z. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol. 1992 Jan; 80(1):40-8. PMID: 1311195.
      Citations: 12     Fields:    Translation:HumansCells
    447. Estrov Z, Kurzrock R, Talpaz M, Blake M, Gutterman JU. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol. 1991 Dec; 63(6):297-301. PMID: 1756190.
      Citations: 1     Fields:    Translation:HumansCells
    448. Kurzrock R, Talpaz M, Estey E, O'Brien S, Estrov Z, Gutterman JU. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia. 1991 Nov; 5(11):985-90. PMID: 1961041.
      Citations: 5     Fields:    Translation:Humans
    449. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991 Sep 15; 78(6):1476-84. PMID: 1715791.
      Citations: 12     Fields:    Translation:Humans
    450. Re GG, Estrov Z, Antoun GR, Felix EA, Pinkel DP, Zipf TF. Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations. Blood. 1991 Aug 01; 78(3):575-80. PMID: 1713508.
      Citations: 5     Fields:    Translation:HumansCells
    451. Kurzrock R, Estrov Z, Wetzler M, Gutterman JU, Talpaz M. LIF: not just a leukemia inhibitory factor. Endocr Rev. 1991 Aug; 12(3):208-17. PMID: 1935819.
      Citations: 8     Fields:    Translation:HumansAnimals
    452. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol. 1991 Jul; 9(7):1241-50. PMID: 2045865.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    453. Estrov Z, Freedman MH. Acute lymphoblastic leukemia blast cells do not inhibit bone marrow hematopoietic progenitor colony formation. Exp Hematol. 1991 Mar; 19(3):221-5. PMID: 1995313.
      Citations:    Fields:    Translation:HumansCells
    454. Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol. 1991 Mar; 9(3):394-9. PMID: 1999709.
      Citations: 15     Fields:    Translation:HumansCells
    455. Estrov Z, Talpaz M, Chou TC, Kurzrock R, Blake M, Gutterman JU. Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. Leukemia. 1991 Feb; 5(2):101-7. PMID: 2020193.
      Citations: 1     Fields:    Translation:HumansCells
    456. Kurzrock R, Estrov Z, Talpaz M, Gutterman JU. Cytokines in tumor therapy. Interleukin-3. Am J Clin Oncol. 1991; 14 Suppl 1:S45-50. PMID: 2048564.
      Citations:    Fields:    Translation:HumansAnimalsCells
    457. Estrov Z, Resnitzky P. [Hematopoietic growth factors and their clinical application]. Harefuah. 1990 Jan 15; 118(2):111-7. PMID: 1690162.
      Citations:    Fields:    Translation:Humans
    458. Cohen A, Madrid-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch HM. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990; 2(1):1-8. PMID: 1965141.
      Citations: 35     Fields:    Translation:HumansCells
    459. Freedman MH, Estrov Z. Congenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect. Am J Pediatr Hematol Oncol. 1990; 12(2):225-30. PMID: 2378417.
      Citations: 3     Fields:    Translation:HumansCells
    460. Estrov Z, Freedman MH. [Recent advances in juvenile chronic myelogenous leukemia]. Harefuah. 1989 May 10; 116(10):538-41. PMID: 2676769.
      Citations:    Fields:    Translation:Humans
    461. Halperin DS, Estrov Z, Freedman MH. Diamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3. Blood. 1989 Apr; 73(5):1168-74. PMID: 2649168.
      Citations: 7     Fields:    Translation:HumansCells
    462. Estrov Z, Berrebi A, Kusminsky G, Resnitzky P. Circulating mononuclear cells from pure red cell aplasia of chronic lymphocytic leukemia suppress in vitro erythropoiesis. Acta Haematol. 1989; 81(4):213-6. PMID: 2502895.
      Citations:    Fields:    Translation:HumansCells
    463. Estrov Z, Freedman MH. Growth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay. Cancer Res. 1988 Oct 15; 48(20):5901-7. PMID: 3048651.
      Citations:    Fields:    Translation:HumansCells
    464. Estrov Z, Halperin DS, Coceani F, Freedman MH. Modulation of human marrow haematopoiesis by leucotrienes in vitro. Br J Haematol. 1988 Jul; 69(3):321-7. PMID: 2841965.
      Citations: 2     Fields:    Translation:Humans
    465. Estrov Z, Cohen A, Gelfand EW, Freedman MH. Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am J Pediatr Hematol Oncol. 1988; 10(4):288-91. PMID: 3239704.
      Citations: 2     Fields:    Translation:HumansCells
    466. Freedman MH, Estrov Z, Chan HS. Juvenile chronic myelogenous leukemia. Am J Pediatr Hematol Oncol. 1988; 10(3):261-7. PMID: 3052147.
      Citations: 4     Fields:    Translation:Humans
    467. Estrov Z, Cohen A, Gelfand EW, Freedman MH. In vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitors. Toxicol In Vitro. 1988; 2(2):131-4. PMID: 20702348.
      Citations: 1     Fields:    
    468. Chan HS, Estrov Z, Weitzman SS, Freedman MH. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol. 1987 Dec; 5(12):1960-7. PMID: 2445935.
      Citations: 10     Fields:    Translation:Humans
    469. Estrov Z, Dubé ID, Chan HS, Freedman MH. Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission. Blood. 1987 Nov; 70(5):1466-9. PMID: 3478101.
      Citations: 1     Fields:    Translation:HumansCells
    470. Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen A. Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia. 1987 May; 1(5):437-41. PMID: 3312841.
      Citations: 7     Fields:    Translation:HumansCells
    471. Estrov Z, Roifman C, Mills G, Grunberger T, Gelfand EW, Freedman MH. The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. Blood. 1987 Apr; 69(4):1161-6. PMID: 3103713.
      Citations: 2     Fields:    Translation:HumansCells
    472. Freedman MH, Estrov Z. Juvenile chronic myelogenous leukaemia and histiocytosis syndromes in children. Lancet. 1987 Mar 28; 1(8535):754. PMID: 2882175.
      Citations:    Fields:    Translation:Humans
    473. Estrov Z, Tawa A, Wang XH, Dubé ID, Sulh H, Cohen A, Gelfand EW, Freedman MH. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood. 1987 Mar; 69(3):757-61. PMID: 3493042.
      Citations: 40     Fields:    Translation:HumansCells
    474. Estrov Z, Lau AS, Williams BR, Freedman MH. Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro. Exp Hematol. 1987 Feb; 15(2):127-32. PMID: 3102273.
      Citations: 3     Fields:    Translation:HumansCells